PX1 Research supplies USA-manufactured, high-purity MIF-1 (Melanostatin-1) for qualified academic and institutional laboratories. Every batch undergoes rigorous third-party verification, including RP-HPLC purity testing, ESI-MS mass confirmation, and quantitative endotoxin screening. Orders placed before 3:00 PM EST ship the same day from our California and Arizona fulfillment centers.
PX1 Research supplies USA-manufactured, high-purity MIF-1 (Melanostatin-1) for qualified academic and institutional laboratories. Every batch undergoes rigorous third-party verification, including RP-HPLC purity testing, ESI-MS mass confirmation, and quantitative endotoxin screening. Orders placed before 3:00 PM EST ship the same day from our California and Arizona fulfillment centers.
When purchasing mif-1 peptide for sale for scientific investigation, laboratory investigators require chemical precision, verified sequence integrity, and complete batch traceability. MIF-1 (Melanocyte Inhibiting Factor-1, also known as Melanostatin-1 or Pro-Leu-Gly-NH2) is a endogenous tripeptide derivative that has drawn substantial interest in neurobiology, behavioral pharmacology, and receptor binding research. PX1 Research supplies high-purity MIF-1 10mg lyophilized powder synthesized in GMP-compliant facilities within the United States, providing research institutions with analytical-grade reagents designed specifically for in vitro assays and animal model experimentation.
Acquiring research-grade MIF-1 requires strict reliance on third-party documentation rather than self-reported supplier metrics. PX1 Research publishes lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited laboratories. These analytical reports confirm high chromatographic purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), verify exact molecular weight via Electrospray Ionization Mass Spectrometry (ESI-MS), and guarantee sub-threshold endotoxin concentrations. By maintaining an uncompromising standard of transparency, PX1 Research ensures that experimental outcomes remain unconfounded by synthetic impurities, residual TFA, or biological contaminants.
MIF-1 is chemically defined as L-prolyl-L-leucyl-glycinamide, representing a tripeptide molecule with the primary sequence Pro-Leu-Gly-NH2 and a molecular formula of C13H24N4O3. With a molecular weight of 284.36 g/mol, MIF-1 is classified as a low-molecular-weight neuropeptide derivative. Structurally, it corresponds to the C-terminal tail of the neurohypophyseal hormone oxytocin, produced naturally via enzymatic cleavage by specific central peptidases.
The C-terminal amidation of the proline-leucine-glycine sequence plays a vital biochemical role, conferring significant enzymatic stability compared to unamidated peptide fragments. In laboratory assays, the chemical structure of MIF-1 exhibits high aqueous solubility and characteristic stability in neutral buffer solutions, making it an ideal candidate for binding affinity measurements, cell culture incubations, and central nervous system receptor assays. Researchers referencing the broader catalog of high-purity research peptides often examine MIF-1 alongside other small regulatory neuropeptides due to its distinct conformational dynamics.
In vitro and animal model studies indicate that MIF-1 operates primarily as a positive allosteric modulator of central dopamine receptors, specifically targeting the D2 and D4 receptor subtypes. Rather than binding directly to the primary agonist orthosteric site, preclinical binding assays suggest MIF-1 binds to an allosteric domain, stabilizing the high-affinity state of the dopamine D2 receptor complex. This conformational stabilization enhances the binding efficacy of endogenous dopamine without directly stimulating the receptor in the absence of primary ligands.
Additionally, preclinical investigations suggest that MIF-1 interacts with central melanocortin signaling pathways and endogenous opioid systems. In vitro radioligand displacement assays demonstrate that MIF-1 can act as an antagonist or allosteric modulator at specific mu-opioid receptor sites, blocking certain non-analgesic signaling cascades induced by enkephalins and morphine derivatives. These dual dopaminergic and neuromodulatory properties make the compound a frequent subject of study in behavioral neurobiology, baseline motor activity models, and reward pathway mechanics.
The primary body of published scientific literature regarding MIF-1 centers on rodent models evaluated for neurobehavioral, extrapyramidal, and endocrine responses. Early animal studies demonstrated that central or systemic administration of MIF-1 influenced dopamine-mediated behavioral responses, including haloperidol-induced catalepsy attenuation and apomorphine-induced stereotypic behavior enhancement. These findings corroborated the hypothesis that MIF-1 enhances postsynaptic dopaminergic transmission in striatal and limbic structures.
Further research highlighted in our MIF-1 research literature portal explores the peptide's activity in chronic stress models, forced swim tests, and learned helplessness paradigms in rodents. In these experimental designs, MIF-1 exhibited distinct behavioral altering properties independent of classical monoamine reuptake inhibition. Because the peptide does not bind directly to monoamine transporters, investigators utilize MIF-1 to dissect alternative neuropeptidergic pathways involved in mood regulation and stress resilience without triggering direct monoaminergic receptor downregulation.
When designing neuropharmacological protocols, investigators frequently compare MIF-1 to other synthetic neuropeptides that target central signaling, cognitive processing, or melanocortin pathways. For instance, Semax is a synthetic ACTH(4-10) heptapeptide derivative widely studied for brain-derived neurotrophic factor (BDNF) expression and neuroprotective activity in ischemic models, whereas MIF-1 primarily targets dopaminergic allosteric modulation and melanocortin interactions. Similarly, Selank, a synthetic analog of the endogenous tetrapeptide tuftsin, exerts its effects primarily through GABAergic modulation and enkephalin degradation inhibition rather than direct dopamine D2 receptor allosteric binding.
In melanocortin system models, scientists also contrast MIF-1 with synthetic melanocortin receptor agonists such as Melanotan II. While Melanotan II functions as a potent, non-selective agonist at MC1R, MC3R, MC4R, and MC5R receptors, MIF-1 originated historically as an inhibitor of melanocyte-stimulating hormone (MSH) release in amphibian models, demonstrating distinct physiological mechanisms in mammalian central nervous system tissues. Exploring these contrasting pathways across our PX1 Research central database allows laboratories to select the precise molecular tool required for their specific receptor assays.
To achieve reproducible data in preclinical research, synthetic peptides must adhere to stringent analytical purity standards. Minor synthetic impurities—such as truncated peptide sequences, deletion peptides, or residual coupling reagents like HOBt and DIC—can interfere with cell culture viability, produce off-target receptor binding, or induce cellular toxicity. PX1 Research subjects every production lot of MIF-1 to comprehensive analytical testing prior to release.
Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) with UV detection at 214 nm, ensuring target chromatographic purity exceeding 99.0%. Mass identity is confirmed via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS), matching the theoretical monoisotopic mass of 284.36 Da. Furthermore, because bacterial lipopolysaccharides (endotoxins) can trigger inflammatory responses in cell cultures and animal tissue models, PX1 Research conducts quantitative Chromogenic LAL (Limulus Amebocyte Lysate) assays to confirm endotoxin levels remain below 0.01 EU/mg.
MIF-1 is supplied as a lyophilized (freeze-dried) sterile powder in sealed borosilicate glass vials to maximize shelf stability. For long-term preservation prior to reconstitution, desiccated lyophilized vials should be stored at -20°C or -80°C, protected from light and atmospheric moisture. Under these conditions, the un-reconstituted peptide remains chemically stable for up to 24 months.
Reconstitution should be conducted within a certified laminar flow hood using aseptic laboratory technique. Due to its polar, amidated tripeptide structure, MIF-1 demonstrates excellent solubility in sterile bacteriostatic water, 0.9% sodium chloride (normal saline), or phosphate-buffered saline (PBS, pH 7.4). After introducing the chosen solvent along the inner glass wall of the vial, gentle swirl motion should be applied until complete dissolution occurs; vortexing or vigorous shaking should be avoided to prevent mechanical shearing or foaming. Reconstituted solutions should be aliquoted into single-use polypropylene tubes and stored at -20°C to prevent freeze-thaw degradation cycles.
PX1 Research serves as a trusted domestic supply partner for university laboratories, biotechnology enterprises, and contract research organizations (CROs). Operating from state-of-the-art facilities in California and Arizona, PX1 eliminates the risks of international customs delays, unpredictable supply chains, and unverified overseas manufacturing standards.
Institutional purchasers requiring larger quantities for multi-stage animal trials or high-throughput screens can utilize our streamlined wholesale research peptide program for bulk pricing, customized vial configurations, and dedicated account support. Every order shipped from PX1 Research includes full batch documentation, lot traceability, and access to raw HPLC and MS spectral data, ensuring absolute compliance with institutional auditing standards.
What is MIF-1 peptide used for in laboratory settings?
MIF-1 (Pro-Leu-Gly-NH2) is used strictly as a research compound in preclinical laboratory studies. Research focuses on its role as an allosteric modulator of dopamine D2 and D4 receptors, its interaction with melanocortin signaling, and its effects in rodent behavioral models of stress and depression.
How does MIF-1 interact with dopamine receptors?
In vitro binding studies indicate that MIF-1 acts as a positive allosteric modulator at dopamine D2 and D4 receptors. It binds to a non-orthosteric site, enhancing agonist binding affinity and stabilizing the active G-protein-coupled receptor conformation.
What analytical testing is performed on PX1 Research MIF-1?
Every lot of MIF-1 supplied by PX1 Research undergoes third-party verification including RP-HPLC purity analysis (confirming >99% purity), ESI-MS mass spectrometry for exact molecular weight confirmation, and Limulus Amebocyte Lysate (LAL) testing for endotoxin levels (<0.01 EU/mg).
In what form is MIF-1 delivered and how should it be stored?
MIF-1 is supplied as a lyophilized (freeze-dried) powder in sealed glass vials. Unreconstituted vials should be stored at -20°C or -80°C in a dry environment protected from light, where it remains stable for up to two years.
What solvents are suitable for reconstituting MIF-1 in a lab?
MIF-1 is highly water-soluble and easily dissolves in sterile research-grade water, 0.9% sterile saline, or standard phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear agitation or repeated freeze-thaw cycles after liquid preparation.
Is MIF-1 approved for human clinical use or medical administration?
No. MIF-1 supplied by PX1 Research is exclusively intended for in vitro assays, cell culture research, and animal model experimentation. It is not approved for human consumption, therapeutic use, or clinical trials.
What is the molecular weight and sequence of MIF-1?
MIF-1 has a chemical sequence of Pro-Leu-Gly-NH2 (L-prolyl-L-leucyl-glycinamide) and a monoisotopic molecular weight of 284.36 g/mol.
How quickly are orders fulfilled and shipped by PX1 Research?
Orders placed before 3:00 PM EST Monday through Friday ship same-day from PX1 Research fulfillment facilities located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.